A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.
A Randomized, Placebo-controlled, Double-dummy, Four-way Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GW876008 and Lorazepam (Comparator) in Healthy Subjects.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
California
-
La Jolla, California, États-Unis, 92093
- GSK Investigational Site
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy males or females aged 18-50 years, inclusive.
- STAI-trait score = or > 40.
- STAI-state score <50th percentile of the normal population distribution.
- Female subjects of non-childbearing.
- Female subjects of childbearing potential must agree to use appropriate contraception.
- Healthy subjects, as determined by a responsible physician
- Body weight ≥ 50 kg (110 lbs), and BMI within the range 19-29.9 kg/m2 inclusive.
- Demonstrates no significant evidence of active disease, physical or mental impairment when assessed by qualified personnel
- Non-smoker (abstinence from smoking for at least 6 months before the start of the study).
- Normal electrocardiogram.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- Read, comprehend, and write English at a sufficient level to complete study-related materials.
- Provide a signed and dated written informed consent prior to study participation
Exclusion Criteria:
- As a result of any of the medical interview, physical examination, evaluation of mental state and psychiatric history or screening investigations the physician responsible considers the subject unfit for the study.
- Any history of suicidal attempts or behaviour.
- Any history or current diagnosis of a psychiatric illness.
- Any history of an endocrine disorder including, but not limited to, diabetes or disorders of the hypothalamus, pituitary, adrenal, or thyroid glands, or gonadal disorder or dysfunction of the reproductive organs.
- Abnormal pepsinogen I level at screening.
- Liver Function Tests (LFTs) elevated above the reference range at pre-study screening that remain elevated with a repeat LFT
- Any other clinically significant laboratory abnormality.
- Positive faecal occult blood test.
- Positive pre-study urine drug/alcohol breath screen.
- Positive pre-study HIV 1/2, Hepatitis B surface antigen and positive Hepatitis C antibody result within 3 months of the start of the study.
- Pre-existing or current Helicobactor pylori infection.
- History of alcohol/drug abuse or dependence within 12 months of the study
- Consumption of grapefruit juice or grapefruit within 14 days prior to the first dose of study medication.
- History of peptic ulcer disease.
- Abnormal screening ECG
- History of long QT syndrome (personal or family) or other cardiac conduction disorder, or other clinically significant cardiac disease.
- Systolic blood pressure < 90mmHg or >140mmHg; diastolic blood pressure < 60mmHg or > 90mmHg; pulse rate < 40bpm or > 90bpm.
- Participation in a clinical trial with a drug or new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
- History or current diagnosis of acute narrow angle glaucoma.
- Where participation in study would result in donation of blood in excess of 500 mL within a 56 day period.
- Current or recent (within one year) gastrointestinal disease; a history of malabsorption, esophageal reflux, irritable bowel syndrome; frequent (more than once a week) occurrence of heartburn; or any surgical intervention (e.g., cholecystectomy) which would be expected to influence the absorption of drugs.
- Average daily caffeine intake equivalent to > 4 cups of coffee or > 6 cups of tea.
- Subjects who are left handed.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
|---|
|
Differences in brain activation elicited by Matching Emotional Face Expression paradigm following single oral doses of GW876008 and lorazepam on day 1, sessions 1-4
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Tests de laboratoire clinique
|
|
|
GW876008 blood levels
Délai: pre-dose & post-dose, sessions 1-4
|
pre-dose & post-dose, sessions 1-4
|
|
clinical rating scales change after dosing: questionnaires collected
Délai: pre-dose & up to 6-8 hours post-dose.
|
pre-dose & up to 6-8 hours post-dose.
|
|
Safety: 12-lead ECG, vital signs, adverse events, clinical labs
|
|
|
fMRI BOLD neuroanatomical structure of the emotional brain neurocircuitry and connectivity
|
|
|
fMRI BOLD Signal characteristics and connectivity
|
|
|
fMRI BOLD Response in the emotional brain neurocircuitry and occipital cortex.
|
|
|
ETCo2 in mm Hg, to be recorded for the duration of the scan session and be synchronized with the single fMRI procedure timing
|
|
|
Visual Analog Scale (VAS) measurements of sleepiness, alertness, calm, tension, and anxiety performed before dosing (baseline), pre-fMRI session, post-fMRI session and just before leaving the facility.
|
|
|
Association between the anxiety trait (STAI-trait, test battery for neuroticism or liability for Anxiety Disorders) collected at screening and the various pharmacodynamic parameters measured in the various testing conditions.
|
|
|
GW876008 concentration to determine pharmacokinetic parameters to be collected twice per session,
|
|
|
Pharmacogenetic (PGx) assessments
|
|
|
Safety and tolerability of GW876008 to include Vital signs semi-supine; respiratory rate, pulse oximetry and ECG.
|
|
|
fMRI BOLD ALS signal.
|
|
|
Heart rate (HR; beats per minute), to be recorded for the whole duration of the scan session and to be synchronized with the single fMRI procedure timing.
|
|
|
Respiratory rate (RR: inspiration per minute), to be recorded for the duration of scan session and be synchronized with the single fMRI procedure timing. .
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Directeur d'études: GSK Clinical Trials, MBChB, MFPM, GlaxoSmithKline
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Effets physiologiques des médicaments
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Dépresseurs du système nerveux central
- Agents autonomes
- Agents du système nerveux périphérique
- Antiémétiques
- Agents gastro-intestinaux
- Agents tranquillisants
- Médicaments psychotropes
- Hypnotiques et sédatifs
- Agents anti-anxiété
- Modulateurs GABA
- Agents GABA
- Anticonvulsivants
- Lorazépam
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- CRH104150
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .